Examples of Recent Technology Transfer Initiatives
- Leo James – Creation of TRIMTECH Therapeutics (2024) to advance targeted protein degradation pipeline for treatment of neurodegenerative conditions.
- Philipp Holliger – Establishment of Sortera Bio (2023) to realise therapeutic potential of Deep Screening technology developed at the LMB.
- Jason Chin – Establishment of Constructive Bio (2022) to develop technologies to assemble DNA on larger scale and reprogramme genomes to engineer non-natural products’
- Greg Winter – Creation of Bicycle Therapeutics (2009) to develop a novel technology platform for the creation of a new generation of biotherapeutics.
- Brad Amos – Setting up of Mesolens Ltd (2009) to develop the technology behind Mesolens microscopy, a new type of imaging that can reach deeper into solid tissues such as embryos or tumours.
- Chris Russo and Lori Passmore – Commercial licensing of gold EM support grids (UltrAuFoil®) to Quantifoil (2015)
- Philipp Holliger – Commercial licensing of an in vitro compartmentalization (IVC) technique to a large biotech company (2017)
- Minmin Yu, Adam Fowle, Wai-ching Hon and Andrew Leslie – Commercial licensing of CombiPuckTM for X-ray crystallography to Mitegen (2017)
- Ernesto Giabatti and Marco Tripodi – Self-inactivating Rabies virus (SiR) – a new tool to study neural networks (2017)
- Fabrice Gorrec – Morpheus® III screen exclusively licensed to Molecular Dimensions (2017)
- Dean Clift, Melina Schuh and Leo James – Trim AwayTM a unique method for the rapid degradation of proteins (2017)
- Mike Gait – Creation of PepGen (2018), a spin-out company which will develop cell penetrating peptides for the treatment of rare genetic disorders
- Anne Bertolotti – Licensing of Raphin1 and phosphatase inhibitors technology to CamPhos Therapeutics (2018)
- Michel Goedert – Tau Transgenic Mice (continued success since 2002)